Warning: Undefined variable $count in /home/seniorca/public_html/wp-content/themes/divi-news-child-healthcare/index.php on line 40
Warning: Undefined variable $count in /home/seniorca/public_html/wp-content/themes/divi-news-child-healthcare/index.php on line 121
Substance Use Disorder M&A Market During 1H 2024
The substance use disorder (SUD) specialty is often the most active submarket in the Behavioral Health Care (BHC) sector, and the first half of 2024 was no exception. According to data captured in the LevinPro HC database, 10 SUD deals were announced during the first six months of 2024, making up about 28% of all BHC deals announced during that time. 1H 2024 activity mirrored the activity witnessed in the first half of 2023, when SUD deals comprised 27% of all BHC deals announced. This consistency reflects sustained investor interest in the SUD treatment space. However, a comparison to the first half of 2022 (36% of BHC deals) and 2021 (34% of BHC deals), when SUD deal totals hit 21... Read More »
Health Catalyst Adds Quarvis Health to Investment Portfolio
Health Catalyst announced at the start of July 2024 that it has added Quarvis Health, Inc. to its portfolio of digital health investments. Quarvis Health is a healthcare technology platform that virtually connects both the aging population and employees/health plan members to their health needs through AI-enabled text-based chat and voice-enabled devices. Quarvis offers a comprehensive solution to engage and navigate users to existing, underutilized benefits, reducing distress and improving behavioral health access and overall well-being. Quarvis Health was formed by the merger of HCC portfolio company Sibly, Inc. with Health4Home, LLC, d/b/a HandsFree Health, also announced in July 2024.... Read More »
PE-Backed MedPharm Merges With CDMO Tergus Pharma
MedPharm, an Ampersand Capital Partners portfolio company, announced on July 8 a merger with Tergus Pharma, backed by Great Point Partners. The combined organization will operate under the MedPharm name, establishing a leading, end-to-end contract development and manufacturing organization (CDMO) with robust scientific, clinical trial manufacturing and commercial production capabilities. Tergus Pharma is a CDMO that provides formulation development, in vitro permeating testing, in vitro release testing, skin biology, analytical services and clinical manufacturing services for branded and generic dermatology products. MedPharm is an end-to-end contract service provider of topical and... Read More »
Specialized Dental Partners Acquires McMurtrey Endodontics
On July 3, Specialized Dental Partners (SDP) announced that it acquired its second Colorado practice of 2024 with the acquisition of McMurtrey Endodontics. McMurtrey Endodontics operates out of one location in Westminster, Colorado. In addition to general dentistry, it provides endodontic services. According to its website, it is run by two providers. A portfolio company of private equity group Quad-C Management, SDP is a leading specialty dental service organization that provides comprehensive support services to endodontic specialists across the United States. According to data captured in the LevinPro HC database, this acquisition represents the 260th Physician Medical... Read More »
Lilly Acquires Morphic Holding, Inc. for $3.2 Billion
On July 8, Lilly (formally known as Eli Lilly and Company) announced that it acquired Morphic Holding, Inc. for an estimated $3.2 billion. Lilly plans to acquire all outstanding shares of Morphic for $57 per share in cash. The purchase price at closing is a premium of around 79% to the closing stock price on Friday. Morphic Holding is a Massachusetts-based biotechnology company that is leading the development of new oral integrin drugs for inflammatory bowel diseases. Its proprietary MInT drug discovery platform combines an expert understanding of integrin dynamics and analytical capabilities with foundational structural biology insights and ongoing input from the Massachusetts-based... Read More »
Pentixapharm Acquires Glycotope’s Target Discovery Unit
On July 3, Pentixapharm announced that it entered into an agreement to acquire certain discovery assets from Glycotope, a Berlin, Germany-based biotechnology company. The assets are aimed at various oncology targets and could be turned into radiopharmaceuticals. Pentixapharm is a radiopharmaceutical development company founded in 2019, with its headquarters in Würzburg, Germany. It develops PentixaFor and PentixaTher, two small peptide-based radiopharmaceuticals that specifically target the CXCR4-receptor expressed in hematological and solid cancers, as well as cardiovascular and endocrine diseases. This acquisition is aimed at doubling Pentixapharm’s pipeline of... Read More »
HiRO Acquires DeltaMed Solutions, Continues to Expand U.S. Footprint
Harvest Integrated Research Organization (HiRO), has announced the successful acquisition of DeltaMed Solutions, headquartered in Somerset, New Jersey. The acquisition, advised by Evercore as financial advisor, marks HiRO’s third CRO acquisition since its establishment in 2020. DeltaMed Solutions is a global life sciences contract research organization (CRO) with a global footprint in the United States and China. DeltaMed Solutions, headquartered in New Jersey, boasts a team of industry professionals with 15-30 years of expertise in serving large to mid-sized pharmaceutical and biotechs. HiRO is a globally oriented CRO with its headquarters in Shanghai, China. With global operations... Read More »
PE-Backed I-MED Enters U.S. Market With Teleradiology Acquisition
Private equity-backed I-MED Radiology Network announced on July 2 that it is entering the U.S. market with the acquisition of San Diego-based teleradiology group StatRad. Founded in 1995, StatRad bills itself as the second largest teleradiology provider in the States. Privately owned by radiologists, StatRad employs more than 90 United States-based physicians performing reads for hundreds of clients and thousands of patients every day, according to its website. I-MED Radiology Network is one of Australia’s leading radiology providers, employing 450 doctors and operating 250 clinics located across Australia. Currently, teleradiology accounts for about 10% of I-MED’s revenue, with its... Read More »
Google Set to Acquire Home Healthcare App CareClic247
Google announced on July 2 that it is set to acquire CareClic247, a prominent home healthcare app. The addition of CareClic247 amplifies Google’s healthcare portfolio and complements Google’s existing healthcare technologies. CareClic247 has developed an app that connects medical and non-medical, in-home caregivers for physically and mentally impaired seniors. The app can send a doctor, nurse or a caregiver to a patient’s home 24/7 on demand. Google focuses on online advertising, search engine technology, cloud computing, computer software, quantum computing, e-commerce, consumer electronics and artificial intelligence. Google’s parent company is Alphabet Inc.... Read More »Schedule a demo
Gain access to the best healthcare and long-term care investment intelligence, data, and analysis.
